ACC/AHA guideline on the secondary prevention of hypercholestrolemia: Difference between revisions
< ACC
m Mmir moved page ACC AHA Guideline on the secondary prevention of hypercholestrolemia to ACC/AHA guideline on the secondary prevention of hypercholestrolemia |
|
(No difference)
| |
Latest revision as of 14:34, 27 February 2018
Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2013 ACC AHA guideline on the treatment of blood cholesterol secondary prevention
Secondary Prevention
| Class I |
| "1. High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age who have clinical ASCVD, unless contraindicated.(Level of Evidence: A)" |
| "2. In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated† or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.(Level of Evidence: A)" |
| Class IIa |
| "1. In individuals with clinical ASCVD >75 years of age, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits and for adverse effects, drug-drug interactions and to consider patient preferences, when initiating a moderate- or high-intensity statin. It is reasonable to continue statin therapy in those who are tolerating it.(Level of Evidence: C)" |
Initiating and Management of Statin Therapy in Individuals with Clinical ASCVD
Clinical ASCVD is defined as acute coronary syndromes or history of MI, stable or unstable angina, coronary revascularization, stroke, or TIA presumed to be of atherosclerotic origin, and peripheral arterial disease or revascularization.